Objectives/Hypothesis: Associations between olfactory function to quality-of-life (QOL) and disease severity in patients with rhinosinusitis is poorly understood. We sought to evaluate and compare olfactory function between subgroups of patients with rhinosinusitis using the Brief Smell Identification Test (B-SIT).
INTRODUCTION
Impaired olfaction is commonly observed in patients with sinonasal disease, with a prevalence reported up to 30% to 60% of this patient population 1, 2 and is a criterion used for the diagnosis of chronic rhinosinusitis (CRS). 3 Despite the high prevalence of olfactory dysfunction in patients with CRS and its link to quality of life (QOL) and disease severity, olfaction is understudied within the larger population as defined by rhinosinusitis.
Olfactory dysfunction in rhinosinusitis is likely multifactorial, due to both a conductive and an uncontrolled inflammatory component that contributes to sensorineural damage of the olfactory neuroepithelium. 4, 5 Therefore, one would predict that olfactory dysfunction would be differentially expressed between patient subgroups of rhinosinusitis, allowing us to differentiate significant inflammatory and structural cofactors that are associated with abnormal olfactory scores.
The goals of this study were to evaluate olfaction in a multi-institutional cohort of patients utilizing a validated instrument of olfaction assessment, systematically compare olfactory function between subgroups of patients with rhinosinusitis-CRS with nasal polypsosis (CRSwNP), CRS without NP (CRSsNP), and recurrent acute rhinosinusitis (RARS)-and to identify significant risk factors associated with olfactory impairment.
MATERIALS AND METHODS

Study Population
Adult patients (aged 18 years) with sinonasal disease were enrolled into a prospective, observational cohort investigation within three academic tertiary rhinology practices: Oregon Health and Science University (Portland, OR), the Medical University of South Carolina (Charleston, SC), and Stanford University (Palo Alto, CA). All research study subjects underwent comprehensive clinical evaluation consisting of physical evaluations, computed tomography (CT) imaging, and bilateral, rigid sinonasal endoscopy examinations as part of the normal standard of care.
Study inclusion criteria consisted of a diagnosis of RARS or CRS as defined by the 2007 Otolaryngology-Head and Neck Surgery Adult Sinusitis Guidelines. 3 Study subjects with RARS were defined as four or more episodes per year of acute bacterial rhinosinusitis without signs or symptoms of rhinosinusitis between episodes. Diagnosis of CRS is defined by persistent symptoms lasting more than 12 weeks. Patients with CRS had undergone previous treatment with oral antibiotics (2 weeks duration) and either topical nasal corticosteroid sprays (3 weeks duration) or a 5-day trial of systemic steroid therapy. Patients were required to complete all necessary enrollment study questionnaires and sign informed consent. The institutional review board at each study site monitored and approved all investigational protocols.
Study participants reported demographic, social, and medical history data including age, gender, race, ethnicity, education level, depression, ciliary dysfunction, recalcitrant disease (failed medical and surgical management)/history of prior sinus surgery, asthma, allergy (confirmed skin prick or radioallergosorbent testing), acetylsalicylic acid (ASA) intolerance, current tobacco use, and history of depression. A history of RARS, CRSwNP, CRSsNP, septal deviation, and inferior turbinate hypertrophy were assessed during the history and physical exam. Because olfactory dysfunction is most likely multifactorial, stemming from a combination of both physical/structural and inflammatory components, comorbid and clinical characteristics were further grouped into physical/structural factors and inflammatory factors. Patients were screened and excluded if they had a diagnosis of disease processes known to be associated with olfactory dysfunction including Alzheimer's disease, traumatic brain injury, Parkinson's disease, schizophrenia, or multiple sclerosis.
Brief Smell Identification Test
Olfactory function was evaluated and measured during the initial enrollment period using the Brief Smell Identification Test (B-SIT). 6 The B-SIT is a validated 12-item, standardized, noninvasive quantitative test of olfactory function that employs 12 microencapsulated odorant strips in a "scratch 'n sniff" format activated with a standard #2 pencil (score range, 0-12). Higher scores indicate better olfactory function, whereas lower scores represent olfactory dysfunction. Both male and female respondents can be classified as having "normal" (B-SIT 9) or "abnormal" (B-SIT <9) olfaction. Normal and abnormal olfactory function was determined in each subject based on young male and female adult norms.
Clinical Disease Severity Measures
CT images were evaluated and staged in accordance with the Lund-Mackay bilateral scoring system (total score range, 0-24), where higher scores represent higher severity of disease as indicated by image opacification in sinonasal regions. 7 Endoscopic examinations were scored using the Lund-Kennedy endoscopy staging system (total score range, 0-20), where higher scores represent worse disease severity. 8 
Disease-Specific QOL Measures
Study participants also completed two CRS-specific QOL instruments: the Rhinosinusitis Disability Index (RSDI) and the 22-item Sinonasal Outcome Test (SNOT-22), which are both validated to characterize CRS-specific disease burden. The RSDI (total score range, 0-120) is a 30-item, disease-specific survey instrument consisting of three subscales that evaluate the impact of CRS on a patient's physical (score range, 0-44), functional (score range, 0-36), and emotional (score range, 0-40) status. Higher reported scores on the RSDI indicate greater disease-specific impacts on QOL and daily function. 9 The SNOT-22 is a validated, treatment outcome measure applicable to chronic sinonasal conditions (total score range, 0-110). 10 Lower total scores on the SNOT-22 suggest better QOL and lower symptom severity. The enrolling physicians at each site were blinded to all survey responses for the study duration.
Statistical Analysis
All clinical and survey data were collected, transferred, and manually entered into a central, relational database (Microsoft Office Access 2007; Microsoft Corp., Redmond, WA) by the study coordinator utilizing standardized clinical research forms. Statistical associations were performed using a commercially obtainable statistical software package (IBM SPSS Statistics v.21.0; IBM Corp. Armonk, NY). Graphical analysis was utilized to evaluate normality and linearity assumptions, and descriptive statistics (means, standard deviations, frequencies, and ranges) were calculated for all patient demographics, disease severity, and QOL measures. Two-tailed, independent sample t tests, Mann-Whitney U tests, and v 2 testing was used to assess bivariate differences between patients with and without normal B-SIT scores where appropriate. Analysis of variance was used to evaluate differences in mean B-SIT scores between patient subgroups with RARS, CRSsNP, and CRSwNP, while adjusting for multiple comparisons using the Bonferroni test. F test statistics, degrees of freedom (df), and corresponding t test statistics were reported where appropriate. Two-tailed Spearman correlation coefficients (r s ) were used to assess nonparametric correlations between B-SIT scores, disease severity measures, and QOL measures.
Multivariate logistic regression was used to identify independent patient characteristics associated with abnormal B-SIT scores (dependent variable), while providing adjusted effect estimates, evidence of collinearity, and identification of effect modification. Two separate models were constructed to identify: (1) structural/anatomical characteristics and (2) inflammationrelated characteristics associated with abnormal olfaction scores. Variables for both models were built using a standard forward selection (P 5.010) and backward elimination (P 5.050) technique in a manual stepwise process.
Finals models were assessed for goodness-of-fit using standard Hosmer-Lemeshow v 2 test statistics. 11 Crude and adjusted effect estimates (b), odds ratios (ORs), and 95% confidence intervals (CIs) were reported with corresponding P values.
RESULTS
Patient Demographics
A total of 445 patients were enrolled between March 2011 and May 2013 and completed the B-SIT and all required study materials. All completed B-SIT scores were dichotomized into normal and abnormal as described above and evaluated across patient characteristics (Table I) .
Those with normal olfaction were more likely to have septal deviation and RARS. Inferior turbinate hypertrophy was more frequent in patients with normal olfaction; however, this trend was not statistically significant. Patients with abnormal olfactory function were found to be slightly older and have a higher prevalence of nasal polyposis, recalcitrant disease/history of prior sinus surgery, asthma, and ASA intolerance.
Olfactory Function
All study subjects (n 5 445) had a mean B-SIT score of 9.1 (3.1). Subjects with normal B-SIT scores (n 5 319; 71.7%) had mean B-SIT scores of 10.8 (1.0) compared to a mean of 4.7 (2.2) for all subjects with abnormal olfaction (n 5 126; 28.3%).
Without separating for normal or abnormal olfactory status, subjects with RARS (n 5 33) and CRSsNP (n 5 260) were found to have significantly higher mean B-SIT scores (10.5 [1.4] Between subgroups with normal olfaction, there were no significant differences found in mean BSIT scores (F 5 0.279; df 5 2; P 5.757). Significant differences were found however between RARS, CRSsNP, and CRSwNP subgroups with abnormal olfaction (F 5 15.031; df 5 2; P <.001). Patients with RARS had significantly higher abnormal mean B-SIT scores when compared to subjects with CRSwNP (7.7 [0.6] vs. 4.0 [2.1]; t 5 3.051; df 5 80; P 5.009). Likewise, subjects with CRSsNP were found to have significantly higher mean abnormal B-SIT scores (5.8 [2.0]) compared to subject with CRSwNP (t 5 24.809; df 5 121; P <.001; Fig. 1 ).
The prevalence of normal olfaction was higher in both subjects with RARS and CRSsNP (90.9% and 83.1%, respectively) compared to subjects with CRSwNP (48.0%; P .009). 
Olfaction and Disease Severity Measures
All patients (n 5 445) were found to have an average endoscopy score of 6.1 (3.9) , range between 0 and 20, and average CT score of 11.7(6.1), range between 0 and 24. Patients with normal olfaction had significantly lower average endoscopy scores and lower average CT scores compared to subjects with abnormal olfaction Table II. Patients with normal olfaction within the subgroups of RARS and CRSsNP were found to have significantly better endoscopy scores (F 5 39.314; df 5 2; P <.001) and CT scores (F 5 34.288; df 5 2; P <.001) compared to subjects with CRSwNP (Table II) . Patients with normal olfaction and RARS had significantly better CT scores (t 5 23.702; df 5 239; P <.001) compared to subjects with CRSsNP.
For patients with abnormal olfaction, subjects with RARS were found to have lower mean endoscopy scores (F 5 32.664; df 5 2; P <.001) and CT scores (F 5 38.404; df 5 2; P <.001) compared to patients with CRSsNP and CRSwNP. Subjects with abnormal olfaction and CRSsNP were found to have significantly lower mean endoscopy scores (t 5 7.764; df 5 121; P <.001) and CT scores (t 5 7.872; df 5 114; P <.001) compared to patients with abnormal olfaction and CRSwNP.
Significant differences in both average endoscopy and average CT scores, among subgroups with RARS, CRSsNP, or CRSwNP, were found for patients with and without normal olfaction (Fig. 2) .
Correlations Between Olfaction and Disease Severity
Significant inverse correlation coefficients were found between B-SIT scores and both endoscopy scores and CT scores for the total cohort and the subgroup of subjects with CRSwNP (Table III) .
Olfaction and QOL Measures
Comparisons of the QOL survey scores from the total cohort (n 5 445) found no significant differences between patients with normal and abnormal B-SIT scores on the SNOT-22 or RSDI total scores (Table IV) . Similar comparisons of subjects within the RARS, CRSsNP, and CRSwNP subgroups found no significant differences in normal and abnormal olfaction on SNOT-22 or RSDI total scores. 
Correlation Coefficients Between Olfaction and QOL Measures
No significant correlations were found between continuous B-SIT olfactory scores and continuous measures of disease-specific QOL for the total cohort, RARS, and CRSsNP. However, when broken down into subgroup classifications of disease status, inverse correlations were found between the B-SIT and QOL as measured by the SNOT-22 and the emotional domain of the RSDI in patients with CRSwNP (Table V) .
Physical/Structural Modeling Variables of Olfactory Dysfunction
Final model selection found that septal deviation (OR: 1.679; 95% CI: 1.004-2.808) was a significant predictor of better olfactory function (P 5.048; 
Inflammatory Modeling Factors of Olfactory Dysfunction
Age and gender adjusted final models for independent variables associated with sinonasal inflammation found that concurrent allergy was not significantly associated with abnormal olfactory function (OR: 0.743; 95% CI: 0.458-1.204; P 5.227; Table VI) and subsequently fell out of final model selection. Similar to structural modeling outcomes, nasal polyposis was strongly associated with worse olfactory function. Recalcitrant disease with a history of prior sinus surgery and ASA intolerance were also significantly associated with worse olfactory function. Goodness-of-fit test statistics again indicated marginal final model fit (v 2 5 8.663; df 5 8; P 5.372), and no evidence of significant collinearity or effect modification was noted.
DISCUSSION
This large cross-sectional study comparatively examines clinical characteristics associated with olfactory dysfunction using an objective measure of olfaction across subgroups of rhinosinusitis. This study demonstrates that olfaction is differentially affected among patients within subgroups of rhinosinusitis, which coincides with previous investigations that have demonstrated that patients with CRS have olfactory disabilities. 12 Disease severity as measured by CT and endoscopy was associated with olfactory dysfunction in the subgroups of rhinosinusitis but did not correlate to disease-specific QOL. Logistical regression models were developed to systematically evaluate independent variables associated with both inflammatory and structural abnormalities and found that nasal polyposis, recalcitrant disease, and ASA sensitivity significantly contributed to olfactory impairment. Age and gender were adjusted for in the B-SIT scoring system and did not require further adjustment as independent variables in the model.
Olfaction is an important neurosensory function that has become increasingly investigated due to its ability to modulate behavior and cognition, influence QOL, and to assess disease severity in multiple pathologic conditions ranging from Alzheimer's disease to CRS. 13 The neurobiology of olfaction involves activation of complex intracellular signaling cascades triggered by specific odorant compounds. Olfactory input travels to secondorder neurons with highly characterized connections to the limbic system and higher cortical regions essential for cognitive functioning. This implies that olfactory function influences input-output signaling in higher cortical centers that may subsequently influence behavior and QOL in CRS. It is unknown if the local inflammatory milieu measured in the sinonasal mucosa correlates to olfactory dysfunction in CRS.
Severe inflammation, as seen on CT and endoscopy, is most likely contributing to not only a conductive component of olfactory dysfunction, but also to sensorineural olfactory dysfunction. Disease severity as measured by CT and nasal endoscopy was found to be significantly associated with olfactory dysfunction such that the objective measures of olfaction correlated with CT and endoscopy scores (P <.001; Table III ). However, this significance was lost when the cohort was broken down into subgroups of rhinosinusitis, as olfaction did not correlate to disease severity in RARS, whereas CRSsNP was weakly associated to endoscopy scores but not to CT scores. Previous studies have demonstrated that disease severity as measured by CT is correlated to olfactory dysfunction in CRS, 14 with olfactory cleft opacification being the most important indicator. 15 As expected, our results are in agreement; disease severity, evident by CT and endoscopy, predicts greater olfactory impairment.
Intuitively, one would predict that olfactory dysfunction would be a predictor of rhinosinusitis diseasespecific QOL, as prior studies suggest that olfaction plays a role in impairing QOL. 4 However, we demonstrate that rhinosinusitis disease-specific QOL measures such as the SNOT-22 and RSDI have limited capability to detect olfactory dysfunction as measured by the B-SIT. This is in accordance with earlier investigations, which were unable to demonstrate any correlations between olfactory impairment and CRS diseasespecific QOL as measured by the RSDI and Chronic Sinusitis Survey (CSS).
14 This is not completely unexpected, as the CSS does not contain any specific olfaction items, whereas the RSDI contains a single olfaction item. Furthermore, when olfactory specific questions were removed from the SNOT-22 (question 21, "Sense of smell/taste") and RSDI (question 7, "Food does not taste good because of my change in smell"), the mild significance we found was lost (all P .239). Overall, although the SNOT-22 and RSDI may have had some capacity to measure the impact of olfactory dysfunction as it relates to QOL, we found these instruments to be limited in their sensitivity to evaluate patients' olfactory discrimination. Investigations undertaken to evaluate associations between olfaction and rhinosinusitis-specific QOL should be explored with specific validated patient-based, olfactory-specific outcomes measures. 13 Those patients with structural abnormalities such as septal deviation and RARS were more likely to be normosmic, whereas those patients historically thought to have more of an inflammatory disease, such as those with asthma, ASA intolerance, and CRSwNP, had worse olfactory dysfunction. The degree of nasal obstruction as it relates to olfaction in CRS is still under investigation as there are conflicting data regarding improving olfaction following surgery that addresses structural defects. Such that nasal obstruction is not predicative of olfactory improvement following nasal septal surgery in patients with CRS. 16, 17 In contrast, patients with nasal obstruction without rhinosinusitis have no improvement in olfaction following surgery. 18 We acknowledge that patients with nasal polyps can be considered to represent both structural and inflammatory components. As such, patients with CRSwNP who undergo polypectomy demonstrate improvement in anosmia at both 6 and 12 months, whereas those with hyposmia showed no improvement following surgery. 19 Likewise, others have shown olfactory dysfunction in patients with CRSwNP with conflicting outcomes in olfactory improvement following surgery. 20, 21 In addition, it is strikingly evident that even within the nasal polyposis group, a large proportion of these patients (48%) have normal olfactory scores. This evidence as a whole, suggests that olfaction in sinonasal disease is most likely multifactorial, consisting of both conductive and sensorineural components.
The strengths of this study include its multiinstitutional prospective design to report olfactory impairment collected from a large cohort of patients with rhinosinusitis using the B-SIT. The B-SIT has several important advantages over other odorant instruments: 1) it has been validated as an objective measure of olfactory discrimination, 2) it has cross-cultural use, 3) it can be easily mailed to study participants for selfadministration, 4) it requires minimal questionnaire time burden (5 minutes) with ease of administration in a busy clinical setting, and 5) the B-SIT correlates to the more commonly used and more burdensome University of Pennsylvania Smell Identification Test instrument in patients with CRS. 22, 23 The primary disadvantage of the B-SIT has to do with its limited ability to differentiate levels of olfactory dysfunction and less sensitivity among those patients with sinonasal disease. However, it has been used to characterize olfactory function in a variety of other diseases and has been used to validate other forms of olfactory function measurements. 24, 25 In addition, odor identification is commonly used in large-scale epidemiological studies, and we demonstrate that the B-SIT can be a tangible option in measuring olfactory dysfunction and identifying risk factors in rhinosinusitis.
CONCLUSION
Patients with sinonasal disease differ in their severity of olfactory dysfunction as measured by the B-SIT instrument. Poor olfaction was significantly associated with disease severity as measured by CT and endoscopy scores, although it was not pervasive among all subgroups of rhinosinusitis. Olfactory dysfunction did not Nasal polyposis was evaluated as both a structural and inflammatory variable, whereas both models were adjusted for age and gender (male reference group).
b 5 b-effect estimate; ASA 5 acetylsalicylic acid; B-SIT 5 Brief Smell Identification Test; CI 5 confidence interval; LB 5 lower bound; OR 5 odds ratio; UB 5 upper bound.
correlate as well to rhinosinusitis-specific QOL measures. Future studies are needed to further elucidate the etiology and pathophysiology of olfactory dysfunction in sinonasal disease.
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